Resection of hepatic and/or pulmonary metastases from colorectal cancer remains the only curative option in stage IV patients, but only 10--20% of patients can be considered for primary resection at the time of diagnosis of metastatic disease. ([@bib2]) With the availability of active chemotherapy regimens, patients initially considered unresectable may be converted into resectable patients and possible long-time survivors. Numerous trials have reported favourable long-time survival and 5-year survival rates ∼40% in these patients ([@bib1]; [@bib16]).

For patients with initially unresectable metastatic disease, the optimal conversion chemotherapy regimen remains uncertain to this date ([@bib25]). Different combination chemotherapy regimens along with monoclonal antibodies have been investigated to induce downsizing and to achieve secondary resectability ([@bib3]; [@bib5]; [@bib11]; [@bib21]; [@bib6]; [@bib20]). Relating to this, patients with liver-limited disease (LLD) who are considered unresectable at the time of diagnosis constitute a specific subgroup denoted as optimal candidates for conversion chemotherapy, secondary resection and long-term survival ([@bib30]).

In view of increasing treatment options for metastatic colorectal cancer (mCRC), the evaluation of prognostic factors at baseline is a major goal to achieve optimal patient selection. Since 2002, Koehne\'s prognostic factors consisting of four baseline clinical and biological parameters (performance status (PS), number of metastatic sites, alkaline phosphatase (AP) level and white blood cell (WBC) count) are a widely used stratification tool for randomised trials ([@bib15]). However, with the definition of specific subgroups in mCRC and the use of combination chemotherapy, the predictive value of Koehne\'s risk classification in clinical subgroups remains unclear ([@bib14]). In 2011, the GERCOR group proposed a simplified prognostic model consisting of lactate dehydrogenase (LDH) and WHO-PS that was investigated and validated within three randomised irinotecan- and oxaliplatin-based trials ([@bib7]). Recently, [@bib8] assessed Koehne\'s prognostic factors in patients treated with chemotherapy and targeted biotherapies and questioned its relevance because of a non-significant distribution of intermediate and good prognostic groups. Accordingly, WHO-PS and WBC count were proposed as potential prognostic factors for OS ([@bib8]).

The purpose of the present analysis was to perform a survival update of the FIRE-1 trial with regard to patients who underwent secondary hepatic resection, LLD and non-LLD patients. Second, to explore the clinical characteristics of LLD- and non-LLD patients, and finally to identify potential prognostic factors in LLD patients based on mature long-term follow-up data of a large randomised phase III trial for unresectable mCRC.

Patients and methods
====================

Patients
--------

The FIRE-1 trial was conducted in the treatment era without the use of targeted therapy comparing first-line chemotherapy with either FUFIRI or mIROX in a German multicentre phase III trial ([@bib10]). In the standard arm, FUFIRI consisted of irinotecan 80 mg m^−2^ as a 0.5-h infusion followed by folinic acid 500 mg m^−2^ applied over 2 h and 5-fluorouracil 2000 mg m^−2^ given as a 24-h infusion weekly six times. In the experimental mIROX arm, patients received irinotecan 80 mg m^−2^ as a 0.5-h infusion weekly six times plus oxaliplatin 85 mg m^−2^ as 2-h infusion on days 15 and 29 of each cycle. In both arms, treatment was repeated every 49 days.

Patients between 18 and 75 years were eligible if they had histologically proven metastatic adenocarcinoma of the colon or rectum without prior chemotherapy for metastatic disease. Patients with resectable metastatic disease were not included in this trial. Prior adjuvant chemotherapy was allowed with a treatment-free interval ⩾6 months and did not include topoisomerase I inhibitors or platinum compounds. A Karnofsky performance status (KPS) ⩾70% (i.e. ECOG 0--1), adequate liver and bone marrow function parameters and bidimensionally measurable tumour lesions were mandatory. Written informed consent was obtained from each patient. Patients were excluded in the presence of symptomatic peritoneal carcinomatosis or brain metastasis, chronic inflammatory bowel disease or bowel obstruction, intolerability of 5-fluorouracil or folinic acid, secondary malignancies (except for basal cell skin cancer or *in situ* carcinoma of the cervix) or known Gilbert\'s syndrome. Further exclusion criteria were administration of other antineoplastic drugs, pregnancy and/or lactation, and radiation treatment within 6 weeks before study entry. Patients were assigned to treatment arms by central randomisation and stratified according to the following factors: KPS (100% *vs* 70--90%), LDH (⩽240 U l^−1^ *vs* \>240 U l^−1^), adjuvant pretreatment (yes *vs* no).

The trial was performed in accordance to the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all participating patients. Approval of the protocol was obtained from the local ethics committee.

Assessment and follow-up
------------------------

Pre-study evaluation included full medical examination, vital signs, CBC and blood chemistry tests (AP, LDH, carcinogenic embryonic antigen and WBC). Tumour-related baseline parameters included primary tumour site (colon or rectum), T- and N-stage of primary, resection of primary tumour, site of metastases, number of metastases and development of metastases (synchronous/metachronous). According to the protocol, the resectability of liver metastases should be discussed with the local hepatobiliary surgeon after 2 cycles of chemotherapy. For evaluation of progression-free survival and overall survival, patients were followed up at 3-month intervals. According to protocol, response evaluation was initially performed according to WHO and subsequently converted into RECIST version 1.1. For investigation of patients who underwent hepatic resection, all medical records of concerned patients were analysed. Follow-up was prolonged by fax and telephone investigation in June 2007 and January 2013 for all patients.

Koehne\'s prognostic model included WHO-PS, WBC count, AP and number of metastatic sites, and retrieved three risk groups: low, intermediate and high risk. ([@bib15]).

Statistical considerations
--------------------------

The primary end point of the FIRE-1 trial was progression-free survival (PFS). Secondary end points were ORR, overall survival (OS), toxicity and secondary resectability of liver metastases. Fisher\'s exact test and the *χ*^2^-test was applied to compare patients\' characteristics and subgroup analyses. Using the Kaplan--Meier estimator, PFS and OS were estimated. Cox proportional hazards regression was used to model the impact of prognostic factors and quantified by hazard ratios (HRs) and corresponding confidence intervals. Prognostic factors were identified by univariate and multivariate logistic regression models relying on the backward elimination algorithm with a selection level of 0.05. For that purpose, for all laboratory variables (carcinogenic embryonic antigen, AP, LDH and WBC) the natural logarithm was applied in order to get a more symmetric distributed variable. All *P*-values were calculated two-sided, and *P*\<0.05 was considered as statistically significant. IBM SPSS (Version 21.0 for Windows, Chicago, IL, USA) was used for statistical evaluation and data management.

Results
=======

Patient population
------------------

Between July 2000 and October 2004, 495 patients from 48 German centres were enrolled. Sixteen patients were considered ineligible because of protocol violation (hyperbilirubinemia, *n*=1) or documentation failure (*n*=15). A total of 479 patients were randomly assigned to receive either the FUFIRI (*n*=238) or the mIROX (*n*=241) regimen. Overall, the treatment arms were well balanced with regard to stratification factors KPS, LDH and adjuvant treatment, and other patient or tumour characteristics. ([@bib10]) After the present survival update, the median follow-up time was 55.4 months (95% confidence interval, 50.0--60.7 months) with an event rate of 87.1% for overall survival.

Patient characteristics
-----------------------

Baseline parameters and clinical characteristics of patients with LLD (with or without resection of metastases) and non-LLD are shown in [Table 1](#tbl1){ref-type="table"}. Although sex was well balanced between the subgroups, patients with LLD tended to be younger than resected patients and non-LLD patients (median age 61.8, 62.7 and 63.5 years, *P*=0.131). Performance status was significantly better in resected patients (KPS 100% in 63.2% of the patients) than in LLD- (35.2%) or non-LLD patients (39.8%) (*P*\<0.001). Tumour characteristics of the primary were comparable regarding T-stage. Node-positive tumours were documented in 61% of resected patients, 77% of LLD patients and 58% of non-LLD patients (*P*\<0.001). Resection of primary tumour was performed in 94.7% in resected patients and 94.9% of LLD- and 92.9% of non-LLD patients, respectively. Around 75% of resected and LLD patients developed their metastases within 6 months of first diagnosis (synchronous), compared with only 45% of non-LLD patients. Localisation of metastases consequently differed among the three groups with 95% of resected patients suffering from LLD. In non-LLD patients, liver was the most common localisation (69%), followed by lung (57%), lymph node (34%) and peritoneal carcinomatosis (7%). Relating to this, the number of metastatic sites was ⩾2 in 82% of non-LLD patients, whereas only 5% of resected patients had extrahepatic lesions. The levels of AP were significantly lower (⩽300 U l^−1^) in patients who underwent hepatic resection (73.7%) compared with LLD patients (43.3%) and non-LLD patients (49.6%) (*P*\<0.001). Elevated baseline LDH levels were observed in 49% of LLD patients and 39% of non-LLD patients, whereas only 16% of resected patients had LDH levels \>250 U/L (*P*\<0.001). In patients who underwent hepatic resection, WBC count was elevated (⩾8.000 per *μ*l) in 32% compared with 45% of LLD patients and 41% of non-LLD patients (*P*\<0.001). According to Koehne *et al* ([@bib15]), a score based on PS, AP level, number of metastatic sites and WBC count allows the differentiation of three prognostic groups: low, intermediate and high risk. In patients with hepatic resection, 82% were classified 'low risk\' compared with 99% of LLD patients. In non-LLD patients, only 23% were classified as 'low risk\', 55% as 'intermediate risk\' and 14% as 'high risk\' (*P*\<0.001). First-line chemotherapy with FUFIRI as opposed to mIROX was more common in patients who achieved resectability (60.5%) compared with 57% of LLD patients and 47% of non-LLD patients (*P*=0.045).

Best response according to subgroups
------------------------------------

To explore the effect of conversion chemotherapy in unresectable mCRC, best response according to patients who underwent hepatic resection (LLD), LLD and non-LLD patients is summarised in [Table 2](#tbl2){ref-type="table"}. Complete response was observed in 15.2% of resected patients, 8.4% of LLD and 6.2% of non-LLD patients. More than 60% of resected patients could achieve a partial response, compared with only 32.6% of LLD patients (*P*=0.002). The rate of partial response in non-LLD patients was comparable to LLD patients (36.3% *P*=0--446). A total of 10 patients (24.2%) could achieve secondary hepatic resection with stable disease (SD) at best response. Comparable stable disease rates were also achieved by LLD and non-LLD patients (31.6 and 36.3%). Progressive disease was present in 14.9% of LLD and 10.6% of non-LLD patients (*P*=0.422). Response evaluation was not possible in a total of 68 patients.

Progression-free survival and overall survival according to subgroups
---------------------------------------------------------------------

Patients who underwent secondary hepatic resection, showed prolonged PFS (16.6 months) and OS (48.0 months), which were significantly (*P*\<0.001) longer than in not-resected groups. Both not-resected patient groups, LLD- and non-LLD, had a shorter PFS (6.5 months *vs* 8.2 months) and OS (17.0 months *vs* 19.0 months). ([Table 3](#tbl3){ref-type="table"}; [Figure 1A and B](#fig1){ref-type="fig"}).

Prognostic factors for hepatic resection
----------------------------------------

To evaluate prognostic factors for secondary hepatic resection, the following baseline parameters were analysed: age, sex, KPS, localisation of primary tumour, T-stage of primary, N-stage of primary, resection of primary, development of metastases, localization of metastases, number of metastatic sites, adjuvant treatment, AP level, LDH levels, WBC count and treatment arm. In a multivariate logistic regression analysis, the following baseline parameters were significantly associated with achievement of secondary hepatic resection: presence of LLD (OR 13.53), low LDH (OR 0.35), nodal-negative primary (OR 0.38), low AP (OR 0.99) and high KPS (OR 1.05). ([Table 4](#tbl4){ref-type="table"}).

Progression-free survival and overall survival according to Koehne\'s risk groups
---------------------------------------------------------------------------------

By applying risk classification according to Koehne *et al*, median PFS was 7.2 months in the low-risk group and 8.2 months in the intermediate-risk group. In high-risk patients, PFS was only 4.3 months (*P*=0.015). Accordingly, OS was comparable between low- and intermediate-risk patients (21.5 months and 20.4 months), whereas high-risk patients had a significantly shortened OS of only 11.6 months (*P*\<0.001). ([Table 5](#tbl5){ref-type="table"}; [Figure 2A](#fig2){ref-type="fig"}; Figure for PFS not shown).

Prognostic factors for OS in LLD
--------------------------------

By definition, the number of metastatic sites in LLD patients is 'one\'. As this parameter did not work as a differentiating prognostic factor, the Koehne model was not able to distinguish prognostic groups among the subgroup of LLD patients. This is demonstrated by the fact, that 99% of LLD patients showed low-risk characteristics according to this model ([Table 1](#tbl1){ref-type="table"}). Therefore a COX regression analysis was performed to obtain independent prognostic factors for LLD, patients including all available baseline characteristics shown in [Table 1](#tbl1){ref-type="table"}. Within the subgroup of LLD patients, elevated WBC count (HR 1.13; *P*=0.005) and elevated LDH (HR 1.27; *P*=0.018) were the only factors significantly associated with decreased overall survival. ([Table 6](#tbl6){ref-type="table"}).

Overall survival according to WBC count and LDH levels in LLD
-------------------------------------------------------------

According to the two prognostic factors found in the Cox regression analysis, LLD patients were subdivided into three groups: normal LDH level and WBC count (low risk), one abnormal parameter (intermediate risk) or both, WBC count and LDH levels elevated (high risk); low-risk patients had a significantly prolonged median OS of 23.2 months compared with intermediate-risk patients (median OS 16.7 months). For high-risk patients, median OS was only 10.1 months. Multivariate HR was 1.69. ([Table 7](#tbl7){ref-type="table"}; [Figure 2B](#fig2){ref-type="fig"}).

Overall survival according to WBC count and LDH levels within the trial population
----------------------------------------------------------------------------------

To evaluate WBC count and LDH levels also within the whole FIRE-1 study population, again three groups were built according to LDH and WBC baseline levels. For low-risk patients, median OS was 25.2 months. Intermediate-risk patients had median OS of 17.4 months, whereas high-risk patients had an inferior median OS of only 10.6 months. Multivariate HR was 1.68. ([Table 7](#tbl7){ref-type="table"}; [Figure 2C](#fig2){ref-type="fig"}).

Discussion
==========

Within the last 10 years, an increasing number of hepatic resections for colorectal liver metastases could be achieved by multidisciplinary teams including hepatobilliary surgeons and medical oncologists improving survival in selected patients. Relating to this, it was shown that improved outcome of mCRC patients was associated with an increase in hepatic resection in two large cancer centers between 1998 and 2004 ([@bib16]). In the present preplanned subgroup analysis, we report from a randomised phase III trial that enrolled 479 patients from July 2000 to October 2004 ([@bib10]). A total of 38 secondary hepatic resections could be performed resulting in a total resection rate of 7.9%. Within the range of published data, these patients showed favourable long-term survival with median OS of 48.0 months and a 5- and 10-year-survival rate of 39% and 17%, respectively ([@bib23]; [@bib31]). After an extended follow-up time of almost 5 years and an event rate of 87.1%, the present study is based on very mature data. It is also important to note that primary resectability of metastatic disease was an exclusion criterion in the FIRE-1 trial.

Best response evaluation according to RECIST 1.1 confirms the concept of conversion chemotherapy also in the era before monoclonal antibodies could be combined with cytotoxic chemotherapy. Secondary resection of colorectal liver metastases could be achieved with complete response in 15.2%, partial response in 60.5% and stable disease in 26.3% of patients who then underwent hepatic resection. In light of these data, it is important to note that the patient with 'stable disease\' should be evaluated for (technically) secondary resection by a multidisciplinary team. In the present study, we were able to identify five potential prognostic factors for secondary hepatic resection within our trial population: LLD, LDH, node-negative primary tumour, KPS and AP. Although LDH, KPS and AP constitute widely explored prognostic factors for OS, the finding of a node-negative primary tumour being associated with secondary hepatic resection confirms previous findings in resected patients where lymphatic spread of the primary was shown to be a risk factor ([@bib19]; [@bib12]). Relating to this, also more than 75% of patients with secondary hepatic resection developed their (liver) metastases synchronously, which has been shown to display a genetically more aggressive tumour subtype but did not result in unfavourable OS according to a retrospective analysis of the CAIRO trial ([@bib18]; [@bib27]). In our analysis of prognostic factors for secondary hepatic resection, LLD remains the strongest prognostic factor. This finding supports the ESMO guidelines requiring highly effective combination therapy to achieve resectability in potentially resectable group 1 patients ([@bib25]).

Furthermore, the present study aimed to characterise the subgroup of patients with LLD mCRC. Although LLD patients from the CRYSTAL and OPUS trials have been previously indicated as a subgroup with superior benefit from chemotherapy (with or without cetuximab), the outcome in unresectable LLD remains unclear ([@bib30]). The present analysis is, to the best of our knowledge, the first to describe a comparable outcome in non-resected LLD- and non-LLD patients in an irinotecan-based phase III trial. This finding emphasises the fact that LLD conversion into secondary resection by combination chemotherapy is the major goal. Based on the present data, we suggest the liver as the major life-limiting metastatic site in unresected or unresectable mCRC patients.

With the inapplicability of the KPS in LLD patients, our analysis also emphasises the need of customised prognostic scoring tools within this important subgroup. Although two previous analyses form French working groups were able to confirm WHO performance status as an independent prognostic factor, WBC count could not be evaluated by the GERCOR group because of missing data and LDH vice versa in the study performed by Desot *et al* ([@bib7]; [@bib8]). In contrast, KPS was not found to be a prognostic factor in our analysis of 215 LLD patients, with the limitation that patients with KPS \<60% were not included in the trial and the comparison between KPS, ECOG and WHO-PS constitute a difficult issue ([@bib28]). In addition, it also needs to be taken into account that the differentiation between ECOG 1 and ECOG 2 is based on the subjective decision of the treating physician and often remains debatable in both, daily routine and clinical trials. With LDH levels and WBC count being used as a cut-off variable (WBC ⩾8.000 per *μ*l and LDH ⩽250 U l^−1^) measured at baseline, the use of these two objective laboratory prognostic factors seems to be advantageous ([@bib28]).

Elevated LDH levels have been shown to be widely associated with poor outcome in several cancer entities including mCRC ([@bib29]; [@bib13]; [@bib7]; [@bib9]). Relating to this, elevated LDH levels in mCRC were linked to activation of hypoxia-inducible factor-related genes in aggressive tumour phenotypes bearing accelerated growth kinetics ([@bib17]). Notwithstanding, it is important to note that LDH may be also influenced by comorbidities such as systemic infection, bone marrow disorders and liver and lung insufficiency particularly outside of clinical trials, where exclusion criteria do not apply.

Also high levels of WBCs, absolute neutrophil count and neutrophil lymphocyte ratio are allied to poor survival in mCRC ([@bib15]; [@bib24]; [@bib22]). Although the role of the innate immune system in cancer development, metastasis and tumour progression is incompletely understood, leucocytes have been found to be involved in progression phases of carcinogenesis by activation and stimulation of growth factors and angiogenesis ([@bib4]; [@bib26]).

One limitation of the present analysis is the small fraction of patients who underwent hepatic surgery. Also, the decision to perform hepatic resection was not validated centrally, but was taken in the local trial centres by oncologists and hepatobiliary surgeons. Therefore, an independent review of hepatic imaging and response as well as independent surgical review on respectability could not be performed in our patients. It is also important to note that in this trial mainly patients with good performance status (KPS 100% in 63% of patients) underwent hepatic resection. This also may have influenced the OS in this subgroup as well as the OS in the whole trial population. But as surgical intervention may outline a selection process *per se*, this may concern many survival reports on patients with metastasectomy. Second, the findings of prognostic factors in LLD patients are only suggestive and need to be confirmed and validated in further analyses. In this regard, further research on conversion chemotherapy is needed to define the optimal regimen leading to secondary resectability and long-term survival.

The proposed prognostic score is based on two baseline parameters, LDH and WBC count, which can easily be obtained and reproduced. Application of this score may help to select patients within clinical trials and may contribute to an optimisation of conversion therapy for mCRC patients.
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![**(A) Progression-free survival in patients who underwent liver resection, LLD and non-LLD. (B) Overall survival in patients underwent liver resection, LLD and non-LLD.** Abbreviations: LR=liver resection; LLD=liver-limited disease; non-LLD=non-liver-limited disease; OS=overall survival; PFS=progression-free survival.](bjc2013475f1){#fig1}

![**(**A**) Overall survival in patients according to Köhne\'s risk classification (FIRE-1 trial population; *n*=479). (**B**) Overall survival according to FIRE prognostic score (LDH + WBC) (LLD population). (**C**) Overall survival according to FIRE prognostic score (LDH + WBC) (FIRE-1 trial population).** Abbreviations: Low risk=WBC count and LDH levels not elevated; Intermediate risk=WBC count or LDH levels elevated; High risk=WBC count and LDH levels elevated; OS=overall survival.](bjc2013475f2){#fig2}

###### Baseline characteristics

                                      **Hepatic resection,** ***n*****=38**   **LLD,** ***n*****=215**   **Non-LLD,** ***n*****=226**                       
  ---------------------------------- --------------------------------------- -------------------------- ------------------------------ ------- ----- ------ -------------
  **Sex**                                                                                                                                                   
  Male                                                 26                               68.4                         151                70.2    158   69.9      0.975
  Female                                               12                               31.6                          64                29.8    68    30.1         
  **Age at randomisation**                                                                                                                                  
  Median (years)                                      62.7                              61.8                         63.5               0.131               
  Range                                              32--73                            32--78                       22--79                                  
  **Karnofsky performance status**                                                                                                                          
  100%                                                 24                               63.2                          76                35.3    90    39.8   **\<0.001**
  70--90%                                              14                               36.8                         139                64.7    136   60.2         
  **Localization of primary**                                                                                                                               
  Colon                                                23                               60.5                         136                63.3    128   56.6      0.365
  Rectal                                               15                               39.5                          79                36.7    98    43.4         
  **T-stage of primary**                                                                                                                                    
  T1/T2                                                 5                               13.2                          15                 7.0    23    10.2      0.101
  T3/T4                                                33                               86.8                         190                88.4    186   82.3         
  NA                                                   ---                              ---                           10                 4.6    17    7.5          
  **N-stage of primary**                                                                                                                                    
  Nodal negative                                       15                               39.5                          37                17.2    70    31.0   **\<0.001**
  Nodal positive                                       23                               60.5                         165                76.7    130   57.5         
  NA                                                   ---                              ---                           13                 6.0    26    11.5         
  **Resection of primary**                                                                                                                                  
  No                                                    2                               5.3                           11                 5.1    16    7.1       0.673
  Yes                                                  36                               94.7                         204                94.9    210   92.9         
  **Development of metastasis**                                                                                                                             
  Synchronous                                          29                               76.3                         159                74.0    102   45.1   **\<0.001**
  Metachronous                                          9                               23.7                          56                26.0    124   54.9         
  **Localization of metastasis**                                                                                                                            
  Liver                                                38                              100.0                         215                100.0   150   68.5   **\<0.001**
  Liver only                                           36                               94.7                         215                100.0   ---   ---    **\<0.001**
  Lung                                                  2                               5.3                          ---                 ---    123   56.2   **\<0.001**
  Lymph node                                            2                               5.3                          ---                 ---    74    33.8   **\<0.001**
  Peritoneal                                           ---                              ---                          ---                 ---    15    6.8    **\<0.001**
  Other                                                ---                              ---                          ---                 ---    13    5.9    **\<0.001**
  **No. of metastatic sites**                                                                                                                               
  1                                                    36                               94.7                         215                100.0   40    17.7   **\<0.001**
  ⩾2                                                    2                               5.3                          ---                 ---    186   82.3         
  **CEA level at baseline**                                                                                                                                 
  \<200 ng ml^−1^                                      32                               84.2                         132                61.4    146   64.6      0.108
  \>200 ng ml^−1^                                       5                               13.2                          57                26.5    47    20.8         
  NA                                                    1                               2.6                           26                12.1    33    14.6         
  **Alkaline phosphatase**                                                                                                                                  
  ⩽300 U l^−1^                                         28                               73.7                          93                43.3    112   49.6   **\<0.001**
  \>300 U l^−1^                                         9                               23.7                         107                49.8    91    40.3         
  NA                                                    1                                26                           15                 7.0    23    10.2         
  **LDH**                                                                                                                                                   
  ⩽250 U l^−1^                                         32                               84.2                         107                49.8    131   58.0   **\<0.001**
  \>250 U l^−1^                                         6                               15.8                         106                49.3    89    39.4         
  NA                                                   ---                              ---                           2                  0.9     6    2.6          
  **WBC**                                                                                                                                                   
  \<8.000 per *μ*l                                     26                               68.4                         115                53.5    130   57.5      0.224
  ⩾8.000 per *μ*l                                      12                               31.6                          96                44.7    88    40.9         
  NA                                                   ---                              ---                           4                  1.9     8    3.6          
  **Haemoglobin**                                                                                                                                           
  ⩽10 g dl^−1^                                         10                               26.3                          59                27.4    54    23.9      0.739
  \>10 g dl^−1^                                        28                               73.7                         152                70.7    165   73.0         
  NA                                                   ---                              ---                           4                  1.9     7    3.1          
  **Platelet count**                                                                                                                                        
  \<400.000 per *μ*l                                   32                               84.2                         169                78.6    182   80.5      0.666
  ⩾400.000 per *μ*l                                     6                               15.8                          42                19.5    37    16.4         
  NA                                                   ---                              ---                           4                  1.9     7    3.1          
  **Koehne\'s Prognostic Groups**                                                                                                                           
  Low                                                  31                               81.6                         212                98.6    52    23.0   **\<0.001**
  Intermediate                                          6                               15.8                          1                  0.5    125   55.3         
  High                                                 ---                              ---                           2                  0.9    31    13.7         
  NA                                                    1                               2.6                          ---                 ---    18    8.0          
  **Treatment**                                                                                                                                             
  FUFIRI                                               23                               60.5                          94                43.7    121   53.5    **0.045**
  mIROX                                                15                               39.5                         121                56.3    105   46.5         

Abbreviations: CEA=carcinogenic embryonic antigen; LDH=lactate dehydrogenase; FUFIRI=5-fuorouracil/folinic acid/irinotecan; mIROX=modified irinotecan plus oxaliplatin; NA=not assessable; WBC=white blood cell count. Statistically significant *P*-values are shown as bold entries.

###### Best response (RECIST 1.1) according to subgroups

       **Hepatic resection,** ***n*****=38**   **LLD,** ***n*****=215**   **Non-LLD,** ***n*****=226**                                  
  ---- --------------------------------------- -------------------------- ------------------------------ ------ ---- ------ ----------- -------
  CR   5                                       15.2                       18                             8.4    14   6.2       0.211     0.486
  PR   23                                      60.5                       70                             32.6   65   28.8    **0.002**   0.446
  SD   10                                      26.3                       68                             31.6   82   36.3      0.643     0.352
  PD   ---                                     ---                        32                             14.9   24   10.6    **0.011**   0.422
  NA   ---                                     ---                        27                             12.6   41   18.1    **0.031**   0.136

Abbreviations: CR=complete response; LLD=liver-limited disease; NA=not assessable; non-LLD=non-liver-limited disease; PD=progressive disease; PR=partial response; SD=stable disease.

Response evaluation according to RECIST 1.1.

Statistically significant *P*-values are shown as bold entries.

*χ*^2^ between hepatic resection an LLD.

*χ*^2^ between LLD and non-LLD.

###### Survival times according to **s**ubgroups

         **Hepatic resection,** ***n*****=38**   **LLD,** ***n*****=215**   **Non-LLD,** ***n*****=226**   ***P*****-value**                      
  ----- --------------------------------------- -------------------------- ------------------------------ ------------------- ------ ------------ ---------
  PFS                    16.6                           8.6--24.6                       6.5                    5.8--7.2        8.2     7.2--9.2    \<0.001
  OS                     48.0                           42.0--54.0                      17.0                  13.9--20.1       19.0   17.0--21.0   \<0.001

Abbreviations: CI=confidence interval; LLD=liver-limited disease; non-LLD=non-liver-limited disease; OS=overall survival; PFS=progression-free survival.

\*The *P*-value given in the last row of the table reflects the global log-rank P-value over the three subgroups.

###### Multivariate analysis: prognostic factors for hepatic resection (logistic regression)

                          **OR**     **95% CI**   ***P*****-value**
  ----------------------- -------- -------------- -------------------
  Liver-limited disease   13.53     4.28--42.82   \<0.001
  Lactate dehydrogenase   0.35       0.13--0.95   0.039
  N-stage of primary      0.38       0.16--0.86   0.021
  KPS                     1.05       1.00--1.11   0.034
  AP                      0.99      0.986--0.997  0.002

Abbreviations: AP=alkaline phosphatise; KPS=Karnofsky performance status; LDH=lactate dehydrogenase; LLD=liver-limited disease; OR=odds ratio.

###### Survival times according to Koehne\'s risk groups

         **Low risk,** ***n*****=295**   **Intermediate risk,** ***n*****=132**   **High risk,** ***n*****=33**   ***P*****-value**                     
  ----- ------------------------------- ---------------------------------------- ------------------------------- ------------------- ------ ----------- ---------
  PFS                 7.2                               6.4--8.1                               8.2                    7.0--9.3        4.3    1.1--7.5     0.015
  OS                 21.5                              18.5--24.6                             20.4                   18.4--22.3       11.6   8.4--14.8   \<0.001

Abbreviations: PFS=progression-free survival; OS: overall survival; CI=confidence interval.

\*The *P*-value given in the last row of the table reflects the global log-rank *P*-value over the three subgroups.

###### Multivariate analysis: prognostic factors for survival (LLD only) (COX regression)

         **HR**   **95% CI**   ***P*****-value**
  ----- -------- ------------ -------------------
  WBC     1.13    1.04--1.23         0.005
  LDH     1.27    1.04--1.54         0.018

Abbreviations: CI=confidence interval; HR=Hazard ratio; LDH=lactate dehydrogenase; WBC=white blood cell count.

###### Overall survival according to WBC and LDH (FIRE score)

                           **Low risk**    **Intermediate risk**  **High risk**    ***P*****-value**                     
  ------------------------ -------------- ----------------------- --------------- ------------------- ------ ----------- ---------
  LLD patients (*n*=215)   23.2                 18.1--28.1        16.7                13.2--20.1      10.1    5.9--14.4  \<0.001
  FIRE-1 trial (*n*=479)   25.2                 22.9--27.6        17.4                15.3--19.4      10.6    7.8--13.8  \<0.001

Abbreviations: CI=confidence interval; High risk=WBC and LDH elevated; Intermediate risk=WBC or LDH elevated; LLD=liver-limited disease; Low risk=WBC and LDH not elevated; OS=overall survival.

\*The *P*-value given in the last row of the table reflects the global log-rank *P*-value over the three subgroups.

[^1]: These authors contributed equally to this work.
